Obesity is no less chronic, and GLP-1 therapy is no less disease-modifying
GLP-1 RA use continues to increase among the general population, and thus, managing these patients in the perioperative setting is becoming more and more common (Chang et al
plasma cortisol, and urinary free cortisol tests
Over time, stress, pollution, and aging can lower your natural glutathione levels, leading to pigmentation, uneven skin tone, and dullness
Certain patients on GLP-1 medications have experienced acute pancreatitis or even cancer
doi: 10.1111/1753-0407.12891 Summary Keywords diabetic kidney disease, diabetic nephropathy, GLP-1 receptor agonists, liraglutide, semaglutide, dulaglutide Citation Kawanami D and Takashi Y (2020) GLP-1 Receptor Agonists in Diabetic Kidney Disease: From Clinical Outcomes to Mechanisms